Journal of Anesthesiology & Clinical Science

Journal of Anesthesiology & Clinical Science

ISSN 2049-9752
Short report

Intralipid treatment: Is it only the tip of an iceberg? A new suggestion: Bone cement implantation syndrome (BCIS)

Joseph Eldor1*, Vladimir Kotlovker1

*Corresponding author: Joseph Eldor csen_international@csen.com

Author Affiliations :

1. Theoretical Medicine Institute, Jerusalem 91273, Israel.


Abstract

On 1998 it was first showed that intravenous intralipid could prevent or improve resuscitation from cardiovascular collapse by severe bupivacaine overdose in rats. Since then published examples now include toxicities related to verapamil, diltiazem, amlodipine, quetiapine and sertraline, haldoperidol, lamotrigine, olanzapine, propranolol, atenolol, nevibolol, doxepin, dosulepin, imipramine, amitriptyline, glyosphate herbicide, flecainide, venlafaxine, moxidectin, and others. Intralipid treatment is a new treatment for Bone cement implantation syndrome (BCIS) which was never suggested before. Animal studies should be done in order to evaluate this new treatment modality.

Keywords: Intralipid, bupivacaine toxicity, bone cement implantation syndrome (BCIS)

ISSN 2049-9752
Volume 1
Abstract Download